LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aktien・Schrodinger Inc

Schrodinger Inc

Geschlossen

BrancheGesundheitswesen

12.04 0.92

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.9

Max

12.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	-196M -60M
Verkäufe	-29M 59M
EPS	-0.621
Gewinnspanne	-102.456
Angestellte	850
EBITDA	-85M -49M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+57.32% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-13M 950M
Vorheriger Eröffnungskurs	11.12
Vorheriger Schlusskurs	12.04

Nachrichtenstimmung

By Acuity

39%

61%

117 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

23.27 / 26.13 Unterstützung & Widerstand

Schrodinger Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Mai 2026, 23:10 UTC

Heiße Aktien

Stocks to Watch: Agilysys, XP

18. Mai 2026, 18:44 UTC

Wichtige Markttreiber

Claritev Shares Recover After Comments About DOJ

18. Mai 2026, 23:55 UTC

Ergebnisse

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. Mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. Mai 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. Mai 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Mai 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Mai 2026, 20:25 UTC

Ergebnisse

Correct: XP 1Q Total Client Assets BRL1.53T

18. Mai 2026, 20:23 UTC

Ergebnisse

XP 1Q Total Client Assets BRL1.53B

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Adj EPS BRL2.49 >XP

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Rev BRL4.73B >XP

18. Mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. Mai 2026, 19:00 UTC

Ergebnisse

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. Mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. Mai 2026, 18:17 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. Mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. Mai 2026, 16:57 UTC

Akquisitionen, Fusionen, Übernahmen

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. Mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. Mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. Mai 2026, 16:54 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Doesn't Set Out Financial Details of Deal

18. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. Mai 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Buys Canada's Modern Group of Companies

Peer-Vergleich

Kursveränderung

Schrodinger Inc Prognose

Kursziel

By TipRanks

57.32% Vorteil

12-Monats-Prognose

Durchschnitt 18.8 USD 57.32%

Hoch 24 USD

Tief 13 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Schrodinger Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Schrodinger Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

23.27 / 26.13Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

117 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.